Cargando…

Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future

microRNAs (miRNAs) are an important class of non-coding RNA that post-transcriptionally regulate the expression of most protein-coding genes. Their aberrant expression in tumors contributes to each of the hallmarks of cancer. In malignant pleural mesothelioma (MPM), in common with other tumor types,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reid, Glen, Johnson, Thomas G., van Zandwijk, Nico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020748/ https://www.ncbi.nlm.nih.gov/pubmed/32117755 http://dx.doi.org/10.3389/fonc.2020.00105

Ejemplares similares

Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways
por: Williams, Marissa, et al.
Publicado: (2019)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients
por: Lin, Ruby C.Y., et al.
Publicado: (2016)

MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review
por: Lo Russo, Giuseppe, et al.
Publicado: (2018)

Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
por: Wright, Casey M., et al.
Publicado: (2013)

Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins αvβ3 and αvβ5
por: Cheng, Ngan Ching, et al.
Publicado: (2014)

Exploring MicroRNA and Exosome Involvement in Malignant Pleural Mesothelioma Drug Response
por: Johnson, Ben, et al.
Publicado: (2022)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Surgical Treatment of Malignant Peritoneal Mesothelioma: Past, Present, and Future
por: Alexander, H. Richard
Publicado: (2009)

Cell-free microRNAs: potential biomarkers in need of standardized reporting
por: Kirschner, Michaela B., et al.
Publicado: (2013)

Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini‐review
por: Han, Yan‐Qiu, et al.
Publicado: (2020)

Promising therapeutic potential of tumor suppressor microRNAs for malignant pleural mesothelioma
por: Dixit, Shivani, et al.
Publicado: (2022)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019)

Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma
por: Williams, Marissa, et al.
Publicado: (2019)

Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis
por: Jotatsu, Takanobu, et al.
Publicado: (2020)

Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
por: Wadowski, Benjamin, et al.
Publicado: (2021)

Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma
por: Choi, Agnes Y., et al.
Publicado: (2022)

MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma
por: Moody, Hannah L., et al.
Publicado: (2017)

microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma
por: Walter, Robert Fred Henry, et al.
Publicado: (2016)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
por: Rossini, Marika, et al.
Publicado: (2018)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma
por: Zhou, Jian-Guo, et al.
Publicado: (2019)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma
por: Fan, Xiyong, et al.
Publicado: (2019)

Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
por: Yoshikawa, Yoshie, et al.
Publicado: (2020)

Chemotherapy for malignant pleural mesothelioma: past results and recent developments
por: Tomek, S, et al.
Publicado: (2003)

Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
por: Cavallari, Ilaria, et al.
Publicado: (2019)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Malignant Pleural Mesothelioma Epidemiology in the United States From 2000 to 2016
por: Thomas, Akesh, et al.
Publicado: (2021)

Editorial: Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms
por: Mastromarino, Maria Giovanna, et al.
Publicado: (2023)

MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study
por: Mozzoni, Paola, et al.
Publicado: (2017)

MicroRNA and mRNA Features of Malignant Pleural Mesothelioma and Benign Asbestos-Related Pleural Effusion
por: Ak, Guntulu, et al.
Publicado: (2015)

Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
por: Xu, Duo, et al.
Publicado: (2020)

Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma
por: Xu, Xiaoling, et al.
Publicado: (2020)

Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation
por: Ferrari, Luca, et al.
Publicado: (2020)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022)

MicroRNAs – novel biomarkers for malignant pleural effusions
por: Wojczakowski, Wiktor, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vih4eqmeobkds4ivg2chidb87b